

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for March 2025

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mantra Pharma Inc.	M-Amlodipine	Norvasc	AMLODIPINE BESYLATE	2.5 mg	tablet	02468018
Auro Pharma Inc.	Auro-Azilsartan Medoxomil	Edarbi	AZILSARTAN MEDOXOMIL	40 mg	tablet	02547015
Auro Pharma Inc.	Auro-Azilsartan Medoxomil	Edarbi	AZILSARTAN MEDOXOMIL	80 mg	tablet	02547023
Laboratoire Riva Inc.	Riva-Cyclobenzaprine	Flexeril	CYLOBENZAPRINE HYDROCHLORIDE	10 mg	tablet	02242079
Apotex Inc.	Apo-Levothyroxine	Synthroid	LEVOTHYROXINE SODIUM	137 mcg	tablet	02550776